Hirosaki University Hospital ( Site 0123)

Hirosaki, Aomori 036-8563

0 studies enrolling now · 1 studies all time

What they study most

Urothelial Carcinoma

Studies at this site

• Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) — Completed